• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

AstraZeneca's Evusheld loses potency against new omicron subvariant, FDA warns

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Oct 05, 2022 at 10:42: AM
via Monday, amid reports that the antibody combo is ineffective against the latest subvariant of omicron, BA.4.6, the FDA has updated (PDF) its fact sheet for Evusheld, saying it can increase the risk of COVID-19 infection for variants that the product does not neutralize.

article source
 

<



Similar threads

cafead
AstraZeneca&#039;s Evusheld nabs its first global nod as a COVID treatment
Replies
0
Views
232
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Study shows AstraZeneca&#039;s Covid-19 mAb Evusheld may not work against dominant Omicron...
Replies
0
Views
369
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: AstraZeneca&#039;s Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
Replies
0
Views
18
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Relay races toward pivotal trial as breast cancer data tee up clash with AstraZeneca&#039;s Truqap
Replies
0
Views
34
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote